Vulnerability of DHCR7+/− mutation carriers to aripiprazole and trazodone exposure

Željka Korade, Thiago C. Genaro‐Mattos, Keri A. Tallman, Wei Liu, Krassimira Garbett, Katalin Koczok, István Balogh, Károly Mirnics, Ned A. Porter

Journal of Lipid Research · 2017 · 26 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

Smith-Lemli-Opitz syndrome is a recessive disorder caused by mutations in 7-dehydrocholesterol reductase (DHCR)7 with a heterozygous (HET) carrier frequency of 1–3%. A defective DHCR7 causes accumulation of 7-dehydrocholesterol (DHC), which is a highly oxidizable and toxic compound. Recent studies suggest that several antipsychotics, including the highly prescribed pharmaceuticals, aripiprazole (ARI) and trazodone (TRZ), increase 7-DHC levels in vitro and in humans. Our investigation was designed to compare the effects of ARI and TRZ on cholesterol (Chol) synthesis in fibroblasts from DHCR7+/− human carriers and controls (CTRs). Six matched pairs of fibroblasts were treated and their sterol profile analyzed by LC-MS. Significantly, upon treatment with ARI and TRZ, the total accumulation of 7-DHC was higher in DHCR7-HET cells than in CTR fibroblasts. The same set of experiments was repeated in the presence of 13C-lanosterol to determine residual Chol synthesis, revealing that ARI and TRZ strongly inhibit de novo Chol biosynthesis. The results suggest that DHCR7 carriers have increased vulnerability to both ARI and TRZ exposure compared with CTRs. Thus, the 1–3% of the population who are DHCR7 carriers may be more likely to sustain deleterious health consequences on exposure to compounds like ARI and TRZ that increase levels of 7-DHC, especially during brain development. Smith-Lemli-Opitz syndrome is a recessive disorder caused by mutations in 7-dehydrocholesterol reductase (DHCR)7 with a heterozygous (HET) carrier frequency of 1–3%. A defective DHCR7 causes accumulation of 7-dehydrocholesterol (DHC), which is a highly oxidizable and toxic compound. Recent studies suggest that several antipsychotics, including the highly prescribed pharmaceuticals, aripiprazole (ARI) and trazodone (TRZ), increase 7-DHC levels in vitro and in humans. Our investigation was designed to compare the effects of ARI and TRZ on cholesterol (Chol) synthesis in fibroblasts from DHCR7+/− human carriers and controls (CTRs). Six matched pairs of fibroblasts were treated and their sterol profile analyzed by LC-MS. Significantly, upon treatment with ARI and TRZ, the total accumulation of 7-DHC was higher in DHCR7-HET cells than in CTR fibroblasts. The same set of experiments was repeated in the presence of 13C-lanosterol to determine residual Chol synthesis, revealing that ARI and TRZ strongly inhibit de novo Chol biosynthesis. The results suggest that DHCR7 carriers have increased vulnerability to both ARI and TRZ exposure compared with CTRs. Thus, the 1–3% of the population who are DHCR7 carriers may be more likely to sustain deleterious health consequences on exposure to compounds like ARI and TRZ that increase levels of 7-DHC, especially during brain development. Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder caused by mutations of 7-dehydrocholesterol reductase (DHCR)7, the gene that encodes DHCR7, the enzyme that converts 7-dehydrocholesterol (DHC) to cholesterol (Chol); see Fig. 1 for selected sterols in the Chol biosynthesis pathway (1Smith D.W. Lemli L. Opitz J.M. A newly recognized syndrome of multiple congenital anomalies.J. Pediatr. 1964; 64: 210-217Abstract Full Text PDF PubMed Scopus (549) Google Scholar, 2Tint G.S. Irons M. Elias E.R. Batta A.K. Frieden R. Chen T.S. Salen G. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome.N. Engl. J. Med. 1994; 330: 107-113Crossref PubMed Scopus (678) Google Scholar, 3Kelley R.I. Hennekam R.C. The Smith-Lemli-Opitz syndrome.J. Med. Genet. 2000; 37: 321-335Crossref PubMed Scopus (381) Google Scholar, 4Herman G.E. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes.Hum. Mol. Genet. 2003; 12: R75-R88Crossref PubMed Google Scholar, 5Porter F.D. Human malformation syndromes due to inborn errors of cholesterol synthesis.Curr. Opin. Pediatr. 2003; 15: 607-613Crossref PubMed Scopus (100) Google Scholar, 6Porter F.D. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management.Eur. J. Hum. Genet. 2008; 16: 535-541Crossref PubMed Scopus (217) Google Scholar, 7Porter F.D. Herman G.E. Malformation syndromes caused by disorders of cholesterol synthesis.J. Lipid Res. 2011; 52: 6-34Abstract Full Text Full Text PDF PubMed Scopus (335) Google Scholar, 8Kanungo S. Soares N. He M. Steiner R.D. Sterol metabolism disorders and neurodevelopment—an update.Dev. Disabil. Res. Rev. 2013; 17: 197-210Crossref PubMed Scopus (65) Google Scholar). There are nearly 200 mutations in DHCR7 that have been reported to date, most of them within a coding region of 1,425 open reading frame bases (9Waterham H.R. Hennekam R.C. Mutational spectrum of Smith-Lemli-Opitz syndrome.Am. J. Med. Genet. C. Semin. Med. Genet. 2012; 160C: 263-284Crossref PubMed Scopus (56) Google Scholar, 10Balogh I. Koczok K. Szabo G.P. Torok O. Hadzsiev K. Csabi G. Balogh L. Dzsudzsak E. Ajzner E. Szabo L. et al.Mutational spectrum of Smith-Lemli-Opitz syndrome patients in Hungary.Mol. Syndromol. 2012; 3: 215-222Crossref PubMed Scopus (13) Google Scholar, 11Ellingson M.S. Wick M.J. White W.M. Raymond K.M. Saenger A.K. Pichurin P.N. Wassif C.A. Porter F.D. Babovic-Vuksanovic D. Pregnancy in an individual with mild Smith-Lemli-Opitz syndrome.Clin. Genet. 2014; 85: 495-497Crossref PubMed Scopus (12) Google Scholar, 12Oláh A.V. Szabó G.P. Varga J. Balogh L. Csábi G. Csákváry V. Erwa W. Balogh I. Relation between biomarkers and clinical severity in patients with Smith-Lemli-Opitz syndrome.Eur. J. Pediatr. 2013; 172: 623-630Crossref PubMed Scopus (16) Google Scholar, 13Witsch-Baumgartner M. Schwentner I. Gruber M. Benlian P. Bertranpetit J. Bieth E. Chevy F. Clusellas N. Estivill X. Gasparini G. et al.Age and origin of major Smith-Lemli-Opitz syndrome (SLOS) mutations in European populations.J. Med. Genet. 2008; 45: 200-209Crossref PubMed Scopus (49) Google Scholar). Furthermore, a recent analysis of exome sequencing databases led to the conclusion that the carrier frequency of pathogenic DHCR7 mutations is 1–3% in the human population (14Cross J.L. Iben J. Simpson C.L. Thurm A. Swedo S. Tierney E. Bailey-Wilson J.E. Biesecker L.G. Porter F.D. Wassif C.A. Determination of the allelic frequency in Smith-Lemli-Opitz syndrome by analysis of massively parallel sequencing data sets.Clin. Genet. 2015; 87: 570-575Crossref PubMed Scopus (43) Google Scholar). Given the number of known DHCR7 mutations, most SLOS cases are compound heterozygous (HET) with different inherited maternal and paternal alleles. The incidence of clinical SLOS cases has been estimated to be 1 in 10,000–70,000 (8Kanungo S. Soares N. He M. Steiner R.D. Sterol metabolism disorders and neurodevelopment—an update.Dev. Disabil. Res. Rev. 2013; 17: 197-210Crossref PubMed Scopus (65) Google Scholar). Mildly affected patients may have minimal symptoms and severely affected individuals may suffer preterm demise, making ascertainment of clinical incidence problematic (15Linck L.M. Hayflick S.J. Lin D.S. Battaile K.P. Ginat S. Burlingame T. Gibson K.M. Honda M. Honda A. Salen G. et al.Fetal demise with Smith-Lemli-Opitz syndrome confirmed by tissue sterol analysis.Prenat. Diagn. 2000; 20: 238-240Crossref PubMed Scopus (31) Google Scholar). While there are many studies on SLOS patients to date, the health status of HET DHCR7+/− mutation carriers has been less extensively investigated. DHCR7+/− carriers are reported to have marginally higher plasma levels of 7-DHC than DHCR7+/+ controls (CTRs) (16Kelley R.I. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts.Clin. Chim. Acta. 1995; 236: 45-58Crossref PubMed Scopus (212) Google Scholar) and animal studies also argue that a single mutant copy of Dhcr7 might affect homeostasis. The 7-DHC levels are increased in Dhcr7+/− HET mice, with the highest levels of 7-DHC found in the nervous system (17Liu W. Xu L. Lamberson C. Haas D. Korade Z. Porter N.A. A highly sensitive method for analysis of 7-dehydrocholesterol for the study of Smith-Lemli-Opitz syndrome.J. Lipid Res. 2014; 55: 329-337Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar). Furthermore, the Dhcr7+/− mutant mice show increased dominance and elevated head-twitch response to a challenge with a 5-HT2A agonist (18Korade Z. Folkes O.M. Harrison F.E. Behavioral and serotonergic response changes in the Dhcr7-HET mouse model of Smith-Lemli-Opitz syndrome.Pharmacol. Biochem. Behav. 2013; 106: 101-108Crossref PubMed Scopus (13) Google Scholar). Circulating blood levels of 7-DHC in CTR populations are very low, less than 0.5 µg/ul, but recent studies have shown that psychiatric patients taking either aripiprazole (ARI) or trazodone (TRZ) have greatly increased plasma levels of 7-DHC (19Korade Ž. Liu W. Warren E.B. Armstrong K. Porter N.A. Konradi C. Effect of psychotropic drug treatment on sterol metabolism.Schizophr. Res. 2017; 187: 74-81Crossref PubMed Scopus (26) Google Scholar). In addition, a clinical report also noted that 15 of 22 individuals who were treated with either or both ARI and TRZ were misdiagnosed as SLOS patients based upon their 7-DHC plasma levels (20Hall P. Michels V. Gavrilov D. Matern D. Oglesbee D. Raymond K. Rinaldo P. Tortorelli S. Aripiprazole and trazodone cause elevations of 7-dehydrocholesterol in the absence of Smith-Lemli-Opitz syndrome.Mol. Genet. Metab. 2013; 110: 176-178Crossref PubMed Scopus (29) Google Scholar). Furthermore, an unbiased cell culture study of pharmacologically active compounds also identified over 5% of 700 7-DHC-elevating compounds (21Kim H-Y.H. Korade Z. Tallman K.A. Liu W. Weaver K. Porter N.A. of 7-dehydrocholesterol of a of pharmacologically active compounds in Res. PubMed Scopus Google Scholar). a recent of the of DHCR7 on human health that in exposure to DHCR7 during the of to of known of 7-dehydrocholesterol reductase pathway to effects of a J. 16: PubMed Scopus (29) Google Scholar). to DHCR7 as ARI and TRZ, may have a on health and especially their is ARI is a highly prescribed drug in the during The that the carrier frequency of DHCR7+/− mutations is and to that affect enzyme have been reported the of there are of individuals who show increased vulnerability to exposure to DHCR7 the response of DHCR7+/+ and DHCR7+/− HET fibroblasts to compounds that strongly inhibit the of 7-DHC to ARI and Our results suggest that exposure to ARI and TRZ may be deleterious to individuals who are HET carriers of a DHCR7 that ARI and TRZ are of known that affect levels of 7-DHC in cell the studies reported may to a of were from were from cell culture were from and sterol and in study are from was as and was to that have a Chol K.M. G. A. R. S. L. W. et A reductase in cultured fibroblasts from patients with response to by in tissue culture Lipid Res. Full Text PDF PubMed Google Scholar). analysis of the DHCR7 gene was as I. Koczok K. Szabo G.P. Torok O. Hadzsiev K. Csabi G. Balogh L. Dzsudzsak E. Ajzner E. Szabo L. et al.Mutational spectrum of Smith-Lemli-Opitz syndrome patients in Hungary.Mol. Syndromol. 2012; 3: 215-222Crossref PubMed Scopus (13) Google Scholar). of and sequencing was the sequencing to the were on the and data were analyzed the analysis of the DHCR7 gene of pathogenic was to et S. N. S. D. S. J. M. E. E. et and for the of a of the of and and the for Med. 2015; 17: Full Text Full Text PDF PubMed Scopus Google Scholar). In CTR were frequency In CTR of a was in HET In CTR a was in HET the that both were as a DHCR7+/− fibroblasts were from of and confirmed SLOS The affected patients compound HET to and Hennekam R.I. Hennekam R.C. The Smith-Lemli-Opitz syndrome.J. Med. Genet. 2000; 37: 321-335Crossref PubMed Scopus (381) Google compound HET mild compound HET In are very in as most of the patients are compound HET and there are a number of patients with the same for mutations many are or with the same have different has been A is in Fig. mutations are as pathogenic or likely pathogenic DHCR7 sterol and and were in in and are in the The biosynthesis of Chol is a that from the to the sterol of cholesterol and Rev. 2011; PubMed Scopus Google Scholar). The pathway to Chol of parallel the and shown in Fig. DHCR7 is an enzyme of cholesterol and Rev. 2011; PubMed Scopus Google Scholar) that the of 7-DHC or the pathway A cell with DHCR7 to elevated levels of 7-DHC or a is in the levels of 7-DHC be as the to a levels of 7-DHC of cells in culture a method to determine DHCR7 is either by a mutation or by an enzyme (17Liu W. Xu L. Lamberson C. Haas D. Korade Z. Porter N.A. A highly sensitive method for analysis of 7-dehydrocholesterol for the study of Smith-Lemli-Opitz syndrome.J. Lipid Res. 2014; 55: 329-337Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar, A. O. J. de G. M. P. F. R. cholesterol and metabolism in Lipid Res. 2013; Full Text Full Text PDF PubMed Scopus Google Scholar, A. G.S. Salen G. Batta A.K. Chen T.S. S. Defective of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome Lipid Res. 1995; Full Text PDF PubMed Google Scholar, A. C. R. F. P. A of and 7-dehydrocholesterol reductase Med. 2012; 55: PubMed Scopus Google Scholar, M. V. A. M. P. R. by of 7-dehydrocholesterol reductase PubMed Scopus Google Scholar, L. S. K. L. A. C. of on the biosynthesis and of and cholesterol a of in Res. PubMed Scopus (65) Google Scholar). A number of different cell have been to the effects of on Chol biosynthesis. While have and cells (17Liu W. Xu L. Lamberson C. Haas D. Korade Z. Porter N.A. A highly sensitive method for analysis of 7-dehydrocholesterol for the study of Smith-Lemli-Opitz syndrome.J. Lipid Res. 2014; 55: 329-337Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar, H-Y.H. Korade Z. Tallman K.A. Liu W. Weaver K. Porter N.A. of 7-dehydrocholesterol of a of pharmacologically active compounds in Res. PubMed Scopus Google Scholar, Z. Tallman K.A. Liu W. Koczok K. Balogh I. Xu L. K. Porter N.A. The of on sterol 7-dehydrocholesterol in cells and human Med. PubMed Scopus Google Scholar) in the for human fibroblasts an model for experiments S. K.A. Z. K. Human fibroblasts in PubMed Scopus Google Scholar). a for the of the of DHCR7 on a cell a DHCR7 human fibroblasts from DHCR7+/− HET of a SLOS and and from a CTR HET cell were HET for pathogenic or likely pathogenic DHCR7 reported in SLOS on DHCR7+/− mutations are in Fig. to analysis of the of ARI and TRZ on CTR and HET analysis of DHCR7 of the CTR as and in of the CTR cell identified DHCR7 of is a that affect Human the is a that is of has been associated with of the of the of sterol biosynthesis were and are reported in DHCR7+/− and DHCR7+/+ for the cells with DHCR7 are reported in the levels of sterols in cultured fibroblasts were by reported for 7-DHC, and Chol (21Kim H-Y.H. Korade Z. Tallman K.A. Liu W. Weaver K. Porter N.A. of 7-dehydrocholesterol of a of pharmacologically active compounds in Res. PubMed Scopus Google Scholar). of Chol synthesis in the presence of ARI or TRZ is by the of Chol that Chol synthesis in fibroblasts. ARI and TRZ have been shown to have a on sterol as by levels of 7-DHC and by the of or by the in a cell (21Kim H-Y.H. Korade Z. Tallman K.A. Liu W. Weaver K. Porter N.A. of 7-dehydrocholesterol of a of pharmacologically active compounds in Res. PubMed Scopus Google Scholar). the of a drug on making of sterol have been to de novo or Chol during a treatment A. G.S. Salen G. Batta A.K. Chen T.S. S. Defective of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome Lipid Res. 1995; Full Text PDF PubMed Google Scholar, C.A. N. Porter F.D. cholesterol synthesis and of cholesterol synthesis in Smith-Lemli-Opitz syndrome Genet. Metab. 85: PubMed Scopus Google Scholar). the ARI and TRZ studies reported was by the of an and of the which was to fibroblasts during with ARI or TRZ Fig. in Fig. the levels of and during to In report both the of exposure of fibroblasts to ARI and TRZ and the based on sterol The of and are in Fig. Sterol levels be in as as fibroblasts the in the and in (21Kim H-Y.H. Korade Z. Tallman K.A. Liu W. Weaver K. Porter N.A. of 7-dehydrocholesterol of a of pharmacologically active compounds in Res. PubMed Scopus Google Scholar). found for sterol levels between HET and CTR fibroblasts for 7-DHC, and levels of and the for in cells elevated 7-DHC and Chol levels have been reported in fibroblasts from SLOS compared with CTR but levels were reported in studies (16Kelley R.I. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts.Clin. Chim. Acta. 1995; 236: 45-58Crossref PubMed Scopus (212) Google Scholar, A. G.S. Salen G. Batta A.K. Chen T.S. S. Defective of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome Lipid Res. 1995; Full Text PDF PubMed Google levels in cultured CTR and DHCR7 HET are in in a are in There is a of that DHCR7 is of a that sterol W. G. The of cholesterol synthesis, and DHCR7, and Lipid Res. 2015; Full Text Full Text PDF PubMed Scopus Google Scholar). is of that that increase levels of 7-DHC in cell culture cause a increase in changes in levels of 7-DHC and to in The is between DHCR7+/− fibroblasts and but the of ARI and TRZ was in fibroblasts DHCR7+/− and CTR were treated with different of either ARI or TRZ and sterols were in the results for DHCR7+/− HET and the CTR fibroblasts. the with ARI and TRZ in elevated levels of 7-DHC in both HET and CTR cells ARI to be more than TRZ in 7-DHC in both CTR and HET In addition, 7-DHC levels were increased in response to both Chol levels were in the same HET and CTR the in the of Chol in the sterol profile is more in DHCR7+/− HET than in CTR fibroblasts an increased vulnerability of DHCR7+/− HET to both Thus, ARI caused a in the of Chol in the cells from nearly to to for the CTR fibroblasts. The levels of and were affected by treatment and are reported in the The data for of the individual cell the cells DHCR7 of are also reported in the to determine ARI and TRZ by the of Chol or de novo CTR and HET fibroblasts to of the same that the cells were to and ARI or of the levels of newly Chol and by the of in were and levels of were by the same to with the that the in the were higher than the for 7-DHC, and sterols of the total sterols in the cells of The HET and CTR cell a different biosynthesis profile as a of ARI or TRZ for the of found in HET cells was the same was in CTR fibroblasts Fig. the to was found to be higher for HET fibroblasts than the same found in CTR cells of ARI and TRZ The drug is in Fig. D. In the absence of CTR cells Chol more than HET as by the higher for CTR cells and for HET Furthermore, the of ARI and TRZ on HET cells was than the of on CTR fibroblasts. Thus, on treatment with the for HET cells to the for CTR cells the same treatment was to for HET a than reported for the in SLOS fibroblasts C.A. N. Porter F.D. cholesterol synthesis and of cholesterol synthesis in Smith-Lemli-Opitz syndrome Genet. Metab. 85: PubMed Scopus Google Scholar). Chol biosynthesis was by but of the cells of and studies were to of and The effects of ARI on were the of TRZ for exposure to the same drug as by of Fig. Fig. The data for the fibroblasts with DHCR7 are of mutations have been associated with SLOS Fig. a cell with a that DHCR7 to treatment with ARI in a that that of HET than CTR based on the response to TRZ, is more to CTR cells than HET In the cell to treatment with both ARI and TRZ like CTR that is to be pathogenic in the human of the of DHCR7 mutations affect and their on the health of HET The of study be in several ARI and TRZ 7-DHC levels and the in of of to both ARI and TRZ is DHCR7+/+ CTR and DHCR7+/− HET to both ARI and TRZ in the human with HET a response with elevated 7-DHC levels and an is a higher experiments that both ARI and TRZ de novo than the of Chol and The of ARI and TRZ on is more for HET than on CTR The of ARI and TRZ the is the of in the as the of the Chol profile is by Our studies were on studies have for brain the Chol biosynthesis pathway is different tissue the human brain for of total as as of Chol and Chol J.M. metabolism in the Opin. 12: PubMed Scopus Google Scholar, J.M. metabolism in the nervous system during and in the Lipid Res. 45: Full Text Full Text PDF PubMed Scopus Google Scholar). Chol is by DHCR7, the enzyme in the Chol biosynthesis is strongly levels in the brain Z. Z. C. and of cholesterol in mouse PubMed Scopus Google Scholar, S. K. S. A. M. T. M. cholesterol metabolism for PubMed Scopus Google Scholar). The of Chol in the a of and is for and and and as a for Thus, the of ARI and TRZ on human fibroblasts and brain tissue is likely to be very a of and of 7-DHC is that 7-DHC in cells is a deleterious The 7-DHC is a highly L. Porter N.A. for of and sterols in and in PubMed Scopus Google Scholar) and over a in vitro and in L. Korade Z. A. J. Liu W. Lamberson Porter N.A. for 7-dehydrocholesterol in for Smith-Lemli-Opitz syndrome.J. Lipid Res. 2011; 52: Full Text Full Text PDF PubMed Scopus Google Scholar, L. Korade Z. Porter N.A. from of and PubMed Scopus Google Scholar). cell cell and affect N. Xu L. Porter N.A. inhibit the in a from or Scopus (43) Google Scholar). also to a of gene changes that are the and in vitro L. Korade Z. A. J. Liu W. Lamberson Porter N.A. for 7-dehydrocholesterol in for Smith-Lemli-Opitz syndrome.J. Lipid Res. 2011; 52: Full Text Full Text PDF PubMed Scopus Google Scholar, Z. Xu L. R. Porter N.A. of for Smith-Lemli-Opitz syndrome.J. Lipid Res. Full Text Full Text PDF PubMed Scopus Google Scholar, L. Korade Z. K. Porter N.A. of from of 7-dehydrocholesterol in Lipid Res. 2013; Full Text Full Text PDF PubMed Scopus (43) Google Scholar). There is in and mice that DHCR7 mutations to of 7-DHC levels (17Liu W. Xu L. Lamberson C. Haas D. Korade Z. Porter N.A. A highly sensitive method for analysis of 7-dehydrocholesterol for the study of Smith-Lemli-Opitz syndrome.J. Lipid Res. 2014; 55: 329-337Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar, A. G.S. Salen G. Batta A.K. Chen T.S. S. Defective of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome Lipid Res. 1995; Full Text PDF PubMed Google Scholar). of single copy mutations of DHCR7 on health to nearly 200 different mutations in the human population and with a carrier of 1–3% in the in and in European I. Koczok K. Szabo G.P. Torok O. Hadzsiev K. Csabi G. Balogh L. Dzsudzsak E. Ajzner E. Szabo L. et al.Mutational spectrum of Smith-Lemli-Opitz syndrome patients in Hungary.Mol. Syndromol. 2012; 3: 215-222Crossref PubMed Scopus (13) Google Scholar, of 7-dehydrocholesterol reductase pathway to effects of a J. 16: PubMed Scopus (29) Google their on health is A a between and DHCR7 and Chol metabolism and preterm K.M. M. D. J.M. and in of cholesterol metabolism is associated with preterm PubMed Scopus Google Scholar). is also by animal of between Dhcr7+/− HET and mice that mutant mice were more likely to on the dominance and in the response to 5-HT2A (18Korade Z. Folkes O.M. Harrison F.E. Behavioral and serotonergic response changes in the Dhcr7-HET mouse model of Smith-Lemli-Opitz syndrome.Pharmacol. Biochem. Behav. 2013; 106: 101-108Crossref PubMed Scopus (13) Google Scholar). are found in of and Full Text Full Text PDF PubMed Google Scholar). is estimated that for of effects of Rev. PubMed Scopus Google Scholar). Our results that ARI and TRZ are for in the have been extensively and have as very that patients more the of was the most prescribed in the in with of is that the and both ARI and TRZ as in the and studies with have been in during the the to the A recent report that exposure of to ARI may be for the health of and and that ARI exposure might to congenital K.P. N. exposure of a on and in 2014; PubMed Scopus Google Scholar). Human studies also the between and Chol biosynthesis: ARI and TRZ treatment to elevated 7-DHC levels in the to a diagnosis of SLOS in patients treated with compounds (20Hall P. Michels V. Gavrilov D. Matern D. Oglesbee D. Raymond K. Rinaldo P. Tortorelli S. Aripiprazole and trazodone cause elevations of 7-dehydrocholesterol in the absence of Smith-Lemli-Opitz syndrome.Mol. Genet. Metab. 2013; 110: 176-178Crossref PubMed Scopus (29) Google Scholar). be noted that 7-DHC may be to ARI and TRZ of the of of that have a of in human clinical identified compounds that increased 7-DHC levels in cells (21Kim H-Y.H. Korade Z. Tallman K.A. Liu W. Weaver K. Porter N.A. of 7-dehydrocholesterol of a of pharmacologically active compounds in Res. PubMed Scopus Google Scholar). of compounds to ARI and have been as compounds by the and and are in during data suggest that exposure to on and be to the 1–3% of the human population who a of a DHCR7 In is to as is to treatment patients for their to and in of in the 2012; Scholar). argue in the of in response to compounds that the Chol biosynthesis pathway be especially as their may be by both and the same Thus, in the of suggest that treatment with 7-DHC-elevating as ARI and for the population that of the DHCR7 In addition, that the vulnerability to 7-DHC-elevating compounds is most during and brain especially both the and the a single DHCR7 drug exposure maternal may 7-DHC levels a toxic to that in SLOS in deleterious The the who the in the for the of and and in for sequencing with aripiprazole cholesterol reductase heterozygous human frequency residual cholesterol synthesis Smith-Lemli-Opitz syndrome trazodone of

References

33